子宫内膜癌相关下肢淋巴水肿的发生率及危险因素:前瞻性纵向队列研究结果
该前瞻性纵向队列研究纳入235例新诊断子宫内膜癌女性,定期采用生物阻抗光谱(BIS)和自报腿部肿胀(SRLS)评估至诊断后24个月。诊断后24个月下肢淋巴水肿(LLL)发生率按BIS为33%、按SRLS为45%,肥胖女性增至67%(BIS)和54%(SRLS)。较高体重指数与基线淋巴水肿及24个月LLL发生相关,合并症、更广泛淋巴结清扫和化疗也是危险因素。
要点
- 诊断后24个月LLL发生率按BIS为33%、按SRLS为45%,肥胖女性分别增至67%和54%。
- 较高体重指数与基线淋巴水肿及24个月LLL发生风险升高相关。
- 合并症、更广泛淋巴结清扫和化疗与LLL发生风险升高相关。
核心结论
- 子宫内膜癌后LLL常见,尤其在高体重指数、合并症、需更广泛淋巴结清扫或化疗的女性中。
- 未来研究应探讨减重干预作为降低LLL发生率策略的潜力。
研究设计与样本
- 前瞻性纵向妇科癌症队列研究,纳入235例新诊断子宫内膜癌女性,诊断后定期(至多每3个月)评估至24个月。
- 采用生物阻抗光谱(BIS)和自报腿部肿胀(SRLS)评估下肢淋巴水肿。
主要发现
- 诊断后24个月LLL发生率按BIS为33%、按SRLS为45%。
- 限制于肥胖女性时,诊断后24个月LLL发生率按BIS为67%、按SRLS为54%。
- 调整分析后,较高体重指数与基线淋巴水肿风险升高相关(BIS:OR 1.91,95% CI 1.47-2.49,p < .01;SRLS:OR 1.06,95% CI 1.00-1.12,p < .01)。
- 较高体重指数与24个月LLL发生风险相关(BIS:OR 1.29,95% CI 0.99-1.68,p = .055;SRLS:OR 1.06,95% CI 1.02-1.11,p = .008)。
- 按SRLS,合并症与基线淋巴水肿相关(OR 1.43,95% CI 1.15-1.78,p = .001),更广泛淋巴结清扫(OR 1.06,95% CI 1.01-1.12,p = .026)和接受化疗(OR 2.65,95% CI 1.12-6.29,p = .027)为LLL发生的危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on the incidence and risk factors for lower limb lymphedema (LLL) associated with endometrial cancer is limited. Our objective was to use data from a prospective, longitudinal gynecological cancer cohort study to determine LLL incidence up to 24 months post-diagnosis of endometrial cancer and to explore the relationship between personal and treatment-related factors and risk of developing LLL. METHODS: Women recently diagnosed with endometrial cancer (n = 235) were evaluated at regular intervals post-diagnosis (up to 3-monthly) using bioimpedance spectroscopy (BIS) and self-reported leg swelling (SRLS). RESULTS: Incidence of LLL at 24 months post-diagnosis was 33% and 45% according to BIS and SRLS, respectively. When analyses were restricted to obese women, incidence at 24 months post-diagnosis increased to 67% (BIS) and 54% (SRLS). Following adjusted analyses, higher body mass index was associated with higher odds of baseline lymphedema (BIS: OR 1.91, 95% CI 1.47-2.49, p < .01; SRLS: OR 1.06, 95% CI 1.00-1.12, p < .01) and LLL incidence by 24 months post-diagnosis (BIS: OR 1.29, 95% CI: 0.99-1.68, p = .055; SRLS: OR 1.06, 95% CI 1.02-1.11, p = .008). According to SRLS, presence of comorbidities was also associated with baseline lymphedema (OR: 1.43, 95% CI: 1.15-1.78, p = .001), and more extensive lymph node dissection (OR 1.06, 95% CI: 1.01-1.12, p = .026) and receipt of chemotherapy (OR: 2.65, 95% CI: 1.12-6.29, p = .027) were identified as risk factors for lymphedema incidence. CONCLUSIONS: These findings suggest that LLL following endometrial cancer is common, particularly in women with high body mass index, or comorbidities, and those requiring more extensive lymph node dissection or chemotherapy. Future studies should examine the potential of weight loss intervention as a strategy to reduce LLL incidence.
引用
- Pigott A, Obermair A, Janda M, et al. Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study. Gynecol Oncol. 2020. PMID: 32499070. doi:10.1016/j.ygyno.2020.04.702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。